Homology is a genetic medicines company translating proprietary, next generation gene editing and gene therapy technology into novel treatments for patients with rare diseases.

The combination of a management team that has successfully developed and commercialized rare disease therapies, and a new multidimensional technology platform uniquely positions the Company to move beyond the current limitations of gene therapy and editing approaches to improve patient care.

Homology Medicines has built foundational intellectual property on gene editing and gene therapy vectors derived from naturally occurring human adeno-associated viruses (AAVs). The Company's technology is precise, on-target and highly efficient for in vivo editing of genetic mutations. The unique team and technology create a significant opportunity for Homology to rapidly advance a diverse pipeline of new medicines that address and potentially cure the underlying cause of genetic diseases.

Recent News

January 3, 2017
Homology Named Top 20 Life Science Startups to Watch in 2017

November/December, 2016
Homology Featured in PharmaVoice's Trending 2017: Gene Editing

September 15, 2016
Homology Medicines Acquires License to Novel AAV Technology to Develop Treatments for Central Nervous System Disorders

June 6, 2016
Homology Medicines Appoints James Warren, Ph.D. as Vice President of Manufacturing

May 2, 2016
Homology Medicines Emerges with Next Generation Gene Editing Technology Driven by Industry-leading Team in Rare Diseases

Meet the Team

Homology’s world-class management team has successfully developed and commercialized therapies for patients with rare diseases. Think you have what it takes to thrive in this environment? Contact us about careers at Homology.